ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 0951 • ACR Convergence 2024

    A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis

    Stavros Giaglis1, Diego Kyburz2 and Ulrich Walker3, 1Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, 2University Hospital Basel, Basel, Switzerland, 3Basel University Hospital, Basel, Switzerland

    Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
  • Abstract Number: 2518 • ACR Convergence 2024

    Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

    Yesim Ozguler1, Olivier Manches2, Didar Ucar3, Ziyan Lin2, Alireza Khodadadi-Jamayran2, Aristotelis Tsirigos2, Gulen Hatemi1 and Johannes Nowatzky4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2NYU Grossman School of Medicine, New York, NY, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
  • Abstract Number: 0952 • ACR Convergence 2024

    Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population

    Cristina Padilla, Eleanor Valenzi, Tracy Tabib, Banafsheh Nazari, Patrizia Fuschiotti and Robert Lafyatis, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…
  • Abstract Number: 2540 • ACR Convergence 2024

    Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis

    Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 2542 • ACR Convergence 2024

    Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis

    Anders Nguyen1, Miriam Bollmann1, Agnieszka Lastowska2, Anna-Karin Hultgård Ekwall1, Dietmar Zaiss3, Gary Firestein4 and Mattias Svensson5, 1University of Gothenburg, Göteborg, Sweden, 2University of Gothenburg, Goteborg, Sweden, 3University Hospital Regensburg, Regensburg, Germany, 4University of California, San Diego, San Diego, CA, 5University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…
  • Abstract Number: 0967 • ACR Convergence 2024

    Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions

    Hadijat Makinde1, Miranda Gurra1, Salina Dominguez2, Matthew Dapas2, Tyler Therron2, Kathleen Aren3, Marie-Pier Tetreault2, Monique Hinchcliff4, Deborah Winter5 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Yale School of Medicine, Westport, CT, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
  • Abstract Number: 1701 • ACR Convergence 2024

    STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity

    Hyun Hee Kim1, Haochen Jiang2, Tatiana Ort3, Gary Sims3 and Richard Hanna4, 1AstraZeneca, Gaithersburg, MD, 2University of Nebraska, Omaha, NE, 3Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4AstraZeneca, Dickerson, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
  • Abstract Number: 1712 • ACR Convergence 2024

    Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment

    Yulong Tang1, Jiangnan Xie2, Dachun Zhuo1, Qi ZHU3, Jiucun Wang1 and Jing Liu2, 1Fudan University, Shanghai, China (People's Republic), 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
  • Abstract Number: 1766 • ACR Convergence 2024

    STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility

    Conor Gruber1, Angelica Lee2, Sofija Buta2, Marta Martin Fernandez2, Veronique Houdouin3, Jean-Laurent Casanova4, Alice Hadchouel5, Jacinta Bustamante5 and Dusan Bogunovic2, 1Mount Sinai Hospital, New York, NY, 2Columbia University, New York, NY, 3Robert Debré Hospital, Paris, France, 4Rockefeller University, New York, NY, 5Hôpital Necker-Enfants Malades, Paris, France

    Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
  • Abstract Number: 1793 • ACR Convergence 2024

    SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages

    Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
  • Abstract Number: 1796 • ACR Convergence 2024

    Kidney Hematopoietic Stem and Progenitor Cells Contribute to Immune Cell Development and Pathology in Lupus Nephritis

    Hansol Yi1, Seyoung Jung2, Mi-Ra Cho3, Yong-Gil Kim1, Chang-Keun Lee1, Bin Yoo1, Jeongseok Lee2 and Seokchan Hong1, 1Asan medical center, Seoul, Republic of Korea, 2Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 3Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Hematopoiesis primarily occurs in the bone marrow (BM), where hematopoietic stem and progenitor cells (HSPCs) originate. However, non-lymphoid tissues outside the BM can contribute…
  • Abstract Number: 0040 • ACR Convergence 2024

    Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis

    Gary Sims1, Mia Collins2, Natalie Pursell3, Teneema Kuriakose1, Fanyi Jiang4, Kristi Moore5, Lucie Bertrand5, Melissa Lasaro5, Jessica Neisen6, Scott Manetz7, Gabriel Wong8, Patrick Riley5, Iain McInnes9, Kyriakos Konstantinidis10 and David Close8, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Dicerna, Lexington, 4Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 5Alexion, AstraZeneca Rare Disease, New Haven, CT, 6Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 7Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 8Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 9University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 10Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
  • Abstract Number: 1816 • ACR Convergence 2024

    Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages

    Emily Morris1, Helen Jarnagin2, Heetaek Yang3, Alexandra Turnquist2, Michael Whitfield4 and Patricia Pioli5, 1Dartmouth College, Enfield, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth College, West Lebanon, NH, 4Geisel School of Medicine at Dartmouth, Hanover, NH, 5Geisel School of Medicine at Dartmouth, Lebanon, NH

    Background/Purpose: While we have shown that systemic sclerosis (SSc) dermal fibroblasts and macrophages (MØs) engage in reciprocal activation mediated by exosomes via paracrine signaling, the…
  • Abstract Number: 0046 • ACR Convergence 2024

    Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies

    Jeba Atkia Maisha1, Alina Sememenko2, Jun Kim2, Mario Navarrete2, XIAOBO MENG1, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology